Sanofi (SNY) stock analysis

In our weekly check, Sanofi is graded B (A to F). Of 21 checks on debt, profit, cash flow and trend: 15 pass, warnings: 4, red flags: 2.

Sector: Healthcare · Drug Manufacturers—General

Strengths

• Low debt
• Easily covers interest
• Profits backed by cash
• Strong free cash flow

Warning signs

• Margins falling
• Dividend stretched
• Weak EPS growth
• Weak profit growth
• Thin margins

Next earnings report: 2026-10-30

Similar companies

GSK · BMY · PFE · NVO · GILD · AMGN

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks graded D or F lost a third of their value 2-3 times as often as those graded A or B.

Updated 2026-10-03

Open the full analysis